This study demonstrated that GLUT5 inhibition, particularly through agents like 2,5-AM, can impede cancer cell proliferation and induce apoptosis, making it a promising approach for ccRCC treatment. Here, SLC2A5 is linked to nonpapillary renal cell carcinoma.